114 results on '"Caccavale, S."'
Search Results
2. Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study.
- Author
-
Megna M, Balato A, Caccavale S, Cacciapuoti S, Calabrese G, Di Brizzi EV, Di Costanzo L, Manzo R, Marino V, Puca RV, Romano F, Sarno O, Scotto di Luzio G, and Lembo S
- Abstract
Background: Guselkumab is the first approved human IgG1λ monoclonal antibody selectively targeting the p19 subunit of IL23. Its effectiveness and safety were widely reported by clinical trials. However, these results must be confirmed in real life since its safety deals with more complicated subjects with respect to trials. Currently, real-life data on the use of guselkumab following treatment failure with ustekinumab are limited, and existing studies usually show a small cohort and/or a reduced follow-up period. In this context, the aim of our study was to evaluate the use of guselkumab in patients who previously did not respond to ustekinumab after up to 3 years of treatment. Methods: A multicenter retrospective study was performed. The study enrolled patients affected by moderate-to-severe plaque psoriasis undergoing treatment with guselkumab who were attending the Psoriasis Center of nine different centers in the Campania region of Italy. Demographic and clinical features were collected for each patient at baseline. Moreover, data on psoriasis severity and adverse events (AEs) were collected at each follow-up visit (week (W)16-W36-W52-W104-W156). Results: A total of 112 patients (70 male, 62.5%; mean age 54.8 ± 11.7 years old) were enrolled. Of these, 48 (42.9%), 34 (30.4%), and 16 (14.3%) reached 1, 2, and 3 years, respectively, of follow-up under guselkumab. A statistically significant clinical improvement was observed since W16, and sustained effectiveness was reported at each timepoint up to W156. No serious AEs were collected. Moreover, a sub analysis on the body mass index, involvement of difficult-to-treat areas, and presence of psoriatic arthritis (PsA) showed that the presence of PsA or palmoplantar psoriasis was associated with a reduced clinical improvement at W16 and W36, without differences from W52. In contrast, the efficacy of guselkumab does not seem to be affected by the BMI, involvement of fingernails, or location in the genital or scalp area. Conclusions: To sum up, our long-term real-life multicenter retrospective study confirmed the efficacy and safety of guselkumab following ustekinumab discontinuation up to 156 weeks of treatment.
- Published
- 2024
- Full Text
- View/download PDF
3. Efficacy and tolerability of tirbanibulin 1% ointment in the treatment of cancerization field: a real-life Italian multicenter observational study of 250 patients.
- Author
-
Nazzaro G, Carugno A, Bortoluzzi P, Buffon S, Astrua C, Zappia E, Trovato E, Caccavale S, Pellegrino V, Paolino G, Balestri R, Lacava R, Ciccarese G, Verdelli A, Barruscotti S, Valenti M, Toni G, Giacalone S, Zavattaro E, Gironi LC, Mercuri SR, Ribero S, Gisondi P, Sena P, and Marzano AV
- Abstract
Background: Tirbanibulin 1% ointment is approved for the field treatment of Olsen grade I actinic keratoses (AKs) of the face and scalp., Methods: We performed a multicenter retrospective study involving 15 dermatologic units in Italy to investigate the efficacy and tolerability of tirbanibulin in a real-life setting. 250 patients were enrolled. Tirbanibulin, 1% ointment, was applied daily for five consecutive days. The efficacy of treatment was measured with modifications of the Actinic Keratosis Area and Severity Index (AKASI). A satisfactory response was defined by complete (100% reduction in the number of lesions) or partial clearance (75-99%) of treated AKs., Results: Overall, the AKASI score was significantly reduced in the studied population (mean, from 4.1 ± 2.7 to 1.4 ± 1.5; P < 0.001). A satisfactory response was observed in 222 (88.8%) cases. The proportion of satisfactory responses was higher when follow-up was performed after 8 weeks (34/35, 97.1%). The reduction in AKASI was significant in patients with Olsen grade II or III lesions (from 5.3 ± 2.8 to 1.6 ± 1.6; P < 0.001). A satisfactory response was observed in 91/104 (87.5%) cases. AKASI reduction was also significant in patients with trunk or limb AKs (from 7.0 ± 1.3 to 2.0 ± 1.6; P = 0.018) since a satisfactory response was observed in 7/8 (87.5%) cases. Tirbanibulin was well tolerated; all adverse events (AEs) included transient local reactions at the site of treatment. Overall, 231 patients had at least one AE. Only 7 (2.8%) grade 4 AEs were recorded., Conclusion: Our retrospective study confirmed that tirbanibulin 1% ointment is effective and well tolerated in a real-life setting and is also promising for Olsen grade II and grade III AKs and AKs localized on difficult-to-treat areas., (© 2024 The Authors. International Journal of Dermatology published by Wiley Periodicals LLC on behalf of the International Society of Dermatology.)
- Published
- 2024
- Full Text
- View/download PDF
4. Glibenclamide-induced Photoallergic Reaction.
- Author
-
Gostiša ER, Jurakić Tončić R, Caccavale S, and Čeović R
- Published
- 2024
- Full Text
- View/download PDF
5. Keratolytics can replace curettage in daylight photodynamic therapy for actinic keratosis on the face/scalp: A randomized clinical trial.
- Author
-
Caccavale S, Boccellino MP, Brancaccio G, Alfano R, and Argenziano G
- Subjects
- Humans, Scalp, Curettage, Keratolytic Agents, Pain etiology, Photosensitizing Agents therapeutic use, Keratosis, Actinic drug therapy, Keratosis, Actinic surgery, Photochemotherapy
- Abstract
Background: Methyl aminolevulinate (MAL) photodynamic therapy (PDT) is commonly used for field treatment of actinic keratoses (AKs). In standard natural daylight PDT (n-DL-PDT) the first step, after the application of chemical solar filter, is removal of crusts and scales by curettage, followed by the application of MAL cream. Some patients experience intense pain during curettage and stinging after application of the photosensitizer to just curettaged skin., Objectives: To evaluate whether n-DL-PDT without curettage, but preceded by application of keratolytics, would maintain a similar efficacy, based on clinical, dermoscopic, reflectance confocal microscopy (RCM) assessments, safety and patient satisfaction as standard n-DL-PDT with curettage., Methods: Forty patients with multiple AKs on the face and/or scalp were enrolled in this study. Patients were randomized into two groups of treatment as follows: (i) MAL n-DL-PDT without previous curettage, preceded by skin preparation at home with keratolytics (30% urea cream, twice a day for 7 days; -Cur group) and (ii) MAL n-DL-PDT preceded by skin preparation at the hospital with curettage (+Cur group)., Results: Thirty-nine participants completed the study. Four hundred and twenty-one AKs in -Cur group and 337 AKs in +Cur group were treated. The mean reduction in the number of AK lesions 3 months after the treatment was 10.7 (-54.7%) in the -Cur and 10.4 (-58.7%) in the +Cur group. We found that the differences in terms of efficacy and patient satisfaction comparing the two treatment regimens were not statistically significant. The pain score reported during and after daylight exposure was similar and low in both groups. Moreover, no unexpected adverse events occurred during the trial period., Conclusions: According to our results, curettage is not necessary to obtain the full treatment effect of n-DL-PDT. We experienced in a real-life setting that n-DL-PDT protocol could be changed by replacing curettage with keratolytics., (© 2023 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.)
- Published
- 2024
- Full Text
- View/download PDF
6. An Unusual Case of Lichen Striatus Onset Under Dupilumab in a Patient With Alopecia Areata.
- Author
-
Tancredi V, Babino G, Fulgione E, Caccavale S, and Argenziano G
- Published
- 2024
- Full Text
- View/download PDF
7. Pigmented Trichoepitheliomas, Not an Uncommon Variant: A Dermoscopical Insight.
- Author
-
Caccavale S, Boccellino MP, Fiorentino C, and Argenziano G
- Published
- 2024
- Full Text
- View/download PDF
8. New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis.
- Author
-
Tancredi V, Buononato D, Caccavale S, Di Brizzi EV, Di Caprio R, Argenziano G, and Balato A
- Subjects
- Humans, Skin, Cyclic Nucleotide Phosphodiesterases, Type 4, Cytokines, Quality of Life, Eczema drug therapy, Eczema etiology
- Abstract
Chronic hand eczema (CHE) is a common inflammatory skin condition that significantly impacts the quality of life. From work-related disabilities to social embarrassment, pain, and financial costs, the burden on society is substantial. Managing this condition presents challenges such as long-term treatment, poor patient compliance, therapy side effects, and economic feasibility. As a result, significant efforts have been made in this field in recent years. Specifically, the broader understanding of CHE pathogenesis has led to the development of new drugs, both topical and systemic. The aim of this narrative review is to summarize the current available data on hand eczema pathophysiology and explore the resulting developments in drugs for its treatment. A comprehensive search on PubMed and the other main scientific databases was conducted using keywords related to CHE and its pathogenesis. The most relevant pathways targeted by therapies include the JAK-STAT cascade, IL-4, and IL-13 axis, phosphodiesterase 4 enzyme, and chemo-attractant cytokines. In the near future, physicians will have a plethora of therapeutic alternatives. Consequently, they should be well-trained not only in how to use these alternatives but also how to combine these treatments to address the ongoing challenges related to efficacy, tolerability, and safety.
- Published
- 2023
- Full Text
- View/download PDF
9. Clinical-epidemiological aspects of the Monkeypox 2022 epidemic: A multicentre study by the Italian SIDeMaST Group of Sexually Transmitted, Infectious and Tropical Diseases.
- Author
-
Carugno A, Parietti M, Ciccarese G, Campanati A, Diotallevi F, Atzori L, Balestri R, Caccavale S, Bellinato F, Benatti SV, Venturelli S, Vezzoli P, Sena P, and Papini M
- Subjects
- Humans, Italy epidemiology, Mpox (monkeypox), Sexually Transmitted Diseases epidemiology, Communicable Diseases, Epidemics
- Published
- 2023
- Full Text
- View/download PDF
10. A Single Skin Lesion as Expression of Widespread Disease: A Case of Systemic Anaplastic Large Cell Lymphoma With a Cutaneous Onset.
- Author
-
Caccavale S, Tancredi V, Ronchi A, Pagliuca F, Pellerone S, and Vitiello P
- Published
- 2023
- Full Text
- View/download PDF
11. Multiple Pigmented Trichoepitheliomas: A Case Report.
- Author
-
Caccavale S, Fiorentino C, Boccellino MP, Pagliuca F, Jurakic Toncic R, and Argenziano G
- Published
- 2023
- Full Text
- View/download PDF
12. Real-World Experience With Topical 5-Fluorouracil 4% (40 mg/g) Cream for the Treatment of Actinic Keratosis.
- Author
-
Briatico G, Brancaccio G, Scharf C, Di Brizzi EV, Pellerone S, Caccavale S, Giorgio CM, Procaccini EM, Moscarella E, and Argenziano G
- Abstract
Introduction: 5-fluorouracil (5-FU) is one of the most effective topical treatments for actinic keratosis (AK). A new 4% formulation of 5-FU was recently approved in Europe., Objectives: This study aimed at evaluating 4% 5-FU cream safety and effectiveness in a real-world setting., Methods: Adult AK patients were retrospectively selected from the University of Campania Dermatology Unit database. Selection criteria included a diagnosis of non-hyperkeratotic, non-hypertrophic AK (Olsen grade I and II) of the face, ears, and/or scalp, treatment with 4% 5-FU once daily for 4 weeks, and at least 3 follow-up visits (4 and 8 weeks after treatment initiation, and 6 months after treatment end). The primary objectives were to evaluate AK lesions improvement at 8 weeks and relapse rate at 6 months. Patient-reported erythema and burning sensation intensity were also assessed at 4 weeks., Results: Ninety-eight patients were included in this analysis (male/female 80/18, mean age 74.7 years). AK lesions improvement at 8 weeks resulted complete or significant in 74.5% and 20.4% of the patients, respectively. At 6 months, 65.3% of the patients did not show AK relapses. Burning sensation at 4 weeks was reported as light, moderate, or absent by 44.9%, 22.4%, and 31.6% of the patients, respectively. Erythema was reported as light, moderate, or absent by 37.8%, 51%, and 10% of the patients, respectively. Burning sensation and erythema disappeared gradually during follow-up. No other side effects were reported., Conclusions: In this real-world study 4% 5-FU proved to be highly effective for AK lesions clearance with a favorable safety profile.
- Published
- 2023
- Full Text
- View/download PDF
13. Primary Cutaneous B-Cell Lymphomas with Large Cell Morphology: A Practical Review.
- Author
-
Ronchi A, Vitiello P, D'Abbronzo G, Caccavale S, Argenziano G, Sica A, Alfano R, Savarese G, Berretta M, Cozzolino I, and Franco R
- Subjects
- Humans, Skin pathology, Immunohistochemistry, Lymphoma, Large B-Cell, Diffuse pathology, Skin Neoplasms diagnosis, Skin Neoplasms genetics, Skin Neoplasms pathology, Leukemia, Lymphocytic, Chronic, B-Cell
- Abstract
Most primary cutaneous lymphomas consist of T-cell lymphomas or small cell lymphomas; however, the skin may also be affected by lymphomas with large cell morphology, as a primary or secondary localization. A minority of cases consist of primary cutaneous B-cell lymphomas (PCBCLs). PCBCLs are a heterogeneous group of rare neoplasms with an overlapping morphological and immunohistochemical picture of the different subtypes. Nevertheless, differential diagnosis in the setting of this group of neoplasms is mandatory to identify the correct therapy and prognosis, but it may be challenging since, due to the rarity of these neoplasms, they may not always be familiar to pathologists. Indeed, immunohistochemistry may not be enough to distinguish the different histotypes, which overlap in immunohistochemical features. Furthermore, the ever-increasing knowledge of the molecular features of systemic B-cell lymphomas, such as gene rearrangements with clinical significance, has led in recent years to further investigation into the molecular landscape of PCBCLs with large cell morphology. This work aimed to provide a practical diagnostic guide for pathologists dealing with primary cutaneous large B-cell lymphomas.
- Published
- 2023
- Full Text
- View/download PDF
14. Multidisciplinary Approach to the Diagnosis and Therapy of Mycosis Fungoides.
- Author
-
Vitiello P, Sagnelli C, Ronchi A, Franco R, Caccavale S, Mottola M, Pastore F, Argenziano G, Creta M, Calogero A, Fiorelli A, Casale B, and Sica A
- Abstract
Mycosis fungoides is the most common primary cutaneous T-cell lymphoma, characterized by skin-homing CD4+ T cells derivation, indolent course, and low-grade of malignancy. Mycosis fungoides's classic type typically onsets with cutaneous erythematous patches, plaque, and tumor. In WHO-EORTC classification, folliculotropic mycosis fungoides, pagetoid reticulosis, and granulomatous slack skin are recognized as distinct variants of mycosis fungoides, because of their clinical and histological features, behavior, and /or prognosis. Mycosis fungoides often shows diagnostic difficulties, due to its absence of specific features and lesional polymorphism. A patient's treatment requires staging. In about 10% of cases, mycosis fungoides can progress to lymph nodes and internal organs. Prognosis is poor at advanced stage and management needs a multidisciplinary team approach. Advanced stage disease including tumors, erythroderma, and nodal, visceral, or blood involvement needs skin directed therapy associated with systemic drugs. Skin directed therapy includes steroids, nitrogen mustard, bexarotene gel, phototherapy UVB, and photochemiotherapy, i.e., total skin electron radiotherapy. Systemic therapies include retinoids, bexarotene, interferon, histone deacetylase inhibitors, photopheresis, targeted immunotherapy, and cytotoxic chemotherapy. Complexity of mycosis fungoides associated with long-term chronic evolution and multiple therapy based on disease stage need a multidisciplinary team approach to be treated.
- Published
- 2023
- Full Text
- View/download PDF
15. Hidradenitis Suppurativa Burdens on Mental Health: A Literature Review of Associated Psychiatric Disorders and Their Pathogenesis.
- Author
-
Caccavale S, Tancredi V, Boccellino MP, Babino G, Fulgione E, and Argenziano G
- Abstract
Skin, mental health and the central nervous system (CNS) are connected by a deep link. It is not only the aesthetic and sometimes the disfiguring aspects of dermatological conditions that can cause a severe psychological burden; also, different studies have shown how chronic skin-inflammatory diseases may influence the activity of the CNS and vice versa. Moreover, the skin and brain share a common embryogenic origin. Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease affecting the hair follicles of the apocrine regions. The main clinical features are nodules, abscesses, cysts, fistulae and disfiguring scars. Pain and stinking discharge from fistulae are often present. It is not surprising that the psychological burden associated with HS is frequently a challenge in dermatologists' daily routines. Patients often suffer from depression and anxiety, but also from substance abuse, psychotic and bipolar disorders and an increased suicide risk. The aim of this article is to review the main psychiatric disorders associated with HS and their pathophysiology. Research on Pubmed was conducted with the key words Hidradenitis suppurativa, psychiatric, depression, anxiety, bipolar, schizophrenia, abuse, suicidal. A high incidence of psychiatric disorders has been described in HS compared to controls. Hidradenitis suppurativa is not a rare disease, and acknowledging the HS psychological burden, psychiatric-associated diseases and associated biomolecular pathways will help dermatologists to better care for their patients.
- Published
- 2023
- Full Text
- View/download PDF
16. Photodynamic Therapy as an Effective Treatment for Cutaneous Lymphomas.
- Author
-
Caccavale S, Tancredi V, Vitiello P, Sica A, Ronchi A, Franco R, Pastore F, and Argenziano G
- Abstract
Topical photodynamic therapy (PDT) is a non-invasive treatment modality frequently used in dermatology to treat superficial skin cancers but also some inflammatory or infectious dermatoses. PDT appears a more and more promising therapeutic option also for cutaneous lymphomas, either of T- or B-cell origin. It is a well-tolerated treatment and has excellent cosmetic outcomes, less side effects compared to other therapies (steroids, surgery, radiotherapy, and so on), no particular contraindications, and is easily repeatable in case of relapses. However, how PDT works in the treatment of cutaneous lymphoproliferative diseases is poorly understood and the literature data are still controversial. Further randomized, controlled clinical trials involving a greater number of patients and centers with a long follow-up are necessary to assess the efficacy of PDT and establish a unique standardized treatment protocol in relation to the lymphomatous disease and the type, thickness, and location of the lesions.
- Published
- 2022
- Full Text
- View/download PDF
17. Dermatologic Manifestations of Thymoma-associated Multiorgan Autoimmunity (TAMA) Syndrome: Cutaneous Signs of an Immune Dysregulation.
- Author
-
Rossiello L, Lupoli A, Cicala G, De Dominicis G, Tancredi V, and Caccavale S
- Abstract
Competing Interests: Competing interests: None.
- Published
- 2022
- Full Text
- View/download PDF
18. Agminated Nevi of the Foot with Checkerboard and Blaschkoid Distribution.
- Author
-
Ingordo V, Licci N, Caccavale S, and Ferrara G
- Abstract
Competing Interests: Competing interests: None.
- Published
- 2022
- Full Text
- View/download PDF
19. An Aesop's Fable in Dermatology: When the Fox Doesn't Reach the Grapes… Maybe He Is Taking a Sunbath.
- Author
-
Caccavale S, Vitiello P, Badolato S, Calabrese G, Alfano R, and Argenziano G
- Subjects
- Humans, Male, Dermatology, Vitis
- Published
- 2022
20. A case of Melkersson-Rosenthal syndrome successfully treated with hydroxychloroquine.
- Author
-
Caccavale S, Vitiello P, Tancredi V, Sica A, Ronchi A, Franco R, Badolato S, and Argenziano G
- Subjects
- Diagnosis, Differential, Humans, Hydroxychloroquine therapeutic use, Melkersson-Rosenthal Syndrome diagnosis, Melkersson-Rosenthal Syndrome drug therapy
- Published
- 2022
- Full Text
- View/download PDF
21. Dermatofibrosarcoma Protuberans: Experience at a Third-Level Referral Center.
- Author
-
Caccavale S, Martins Basso A, Vitiello P, Ronchi A, Sica A, Verolino P, Toncic RJ, and Argenziano G
- Abstract
Competing Interests: Competing interests: None.
- Published
- 2022
- Full Text
- View/download PDF
22. A case of hidradenitis suppurativa and Darier disease in a patient treated with acitretin: how to kill two birds with one stone.
- Author
-
D'Ambra I, Caccavale S, Ronchi A, Franco R, and Argenziano G
- Subjects
- Acitretin therapeutic use, Humans, Keratolytic Agents therapeutic use, Severity of Illness Index, Darier Disease drug therapy, Hidradenitis Suppurativa complications
- Published
- 2021
- Full Text
- View/download PDF
23. Successful treatment of cutaneous pseudolymphoma with topical methylaminolevulinate photodynamic therapy.
- Author
-
Caccavale S, Vitiello P, Ronchi A, Franco R, Jurakic Toncic R, and Argenziano G
- Subjects
- Humans, Photochemotherapy, Pseudolymphoma drug therapy
- Published
- 2021
- Full Text
- View/download PDF
24. Annular Atrophic Lichen Planus: A Case Report.
- Author
-
Toncic RJ, Lončarić D, Caccavale S, Reñe JG, and Radoš J
- Abstract
Competing Interests: Competing interests:: None.
- Published
- 2021
- Full Text
- View/download PDF
25. A Randomized Double-Blind Parallel-Group Study to Evaluate the Long-Term Effects of a Medical Device Containing 0.3% Octatrienoic Acid in the Treatment of Grade III Actinic Keratosis.
- Author
-
Babino G, Caccavale S, Pinto D, Trink A, Giuliani G, Rinaldi F, and Argenziano G
- Abstract
Introduction: Actinic keratosis (AK) consists of skin lesions with a milder degree of keratinocytic atypia. It can be also referred to as "field of cancerization," which can potentially evolve to cutaneous squamous cell carcinoma (SCC). Several therapeutic options are currently available, but not all are indicated on hyperkeratotic lesions. This study aimed to test the efficacy and tolerability of a medical device containing 2,4,6-octatrienoic acid and urea for the treatment of hyperkeratotic AK lesions., Methods: Seventy male and female subjects with grade III AK were enrolled in this randomized double-blind parallel-group study. The product was applied once daily for three consecutive months. The primary efficacy endpoint was the reduction in the mean number of AK lesions per subject from baseline (T0) to the end of the trial (T1) and 3 months after the end of the treatment period (T2). Therefore, clearance of target AK lesions at the end of the treatment period and local skin reaction score (LSR) versus baseline were evaluated., Results: There was a decrease of mean values from baseline to visit T2 in both treatment groups, but the decrease (versus baseline values) was more evident in the Kerà K2 group than in the placebo group (-42.78, SD 26.53, versus -6.20, SD 31.57), and the difference was statistically significant (p < 0.001). For 70 subjects (56.7%) in the Kerà K2 group and 3 (11.54%) in the placebo group, a significant (p < 0.005) partial clearance was evidenced. The product was well tolerated, and no serious adverse events were reported during the duration of the trial. Subject self-assessment of acceptability, local tolerability, and the cosmetic result was good at both T1 and T2 for both groups., Conclusions: The medical device has demonstrated good efficacy in the reduction of visible AKs, encouraging its use., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
26. Body Mass Index and Melanoma Prognosis.
- Author
-
Cassano N, Caccavale S, Vena GA, and Argenziano G
- Abstract
Introduction: Obesity has been suggested as a risk factor in the progression of malignancies, including melanoma. Most studies defined obesity using body mass index (BMI), although the index is considered an imperfect measure of body composition., Objective: The aim of this article is to examine whether BMI can impact on the prognosis of cutaneous melanoma, regardless of anti-tumor therapy. The relationship between BMI and specific prognostic factors in melanoma patients has been reviewed., Methods: Literature search was conducted on PubMed using the terms "melanoma" and "body mass index" or "obesity". We selected articles, published up to 30 November 2020, examining the prognostic aspects of melanoma. Articles evaluating the risk and incidence of melanoma were excluded as well as studies regarding morbidity and complications following surgical procedures, or those performed in metastatic melanoma patients treated with anti-tumor therapies., Results: Mixed results have emerged from studies assessing the clinical outcomes in melanoma patients in relation to BMI. More consistent data seem to support the relationship between BMI and Breslow thickness., Conclusions: Studies that focus specifically on the link between obesity and melanoma prognosis are limited; further research is needed to deepen our knowledge on this link., Competing Interests: Competing interests: The authors have no conflicts of interest to disclose., (©2021 Cassano et al.)
- Published
- 2021
- Full Text
- View/download PDF
27. Floppy eyelid syndrome associated with neurofibromatosis type 1: the first report of a possible correlation.
- Author
-
Caccavale S, Vitiello P, Ronchi A, Verolino P, Pieretti G, and Argenziano G
- Subjects
- Eyelids, Humans, Eyelid Diseases diagnosis, Eyelid Diseases etiology, Neurofibromatosis 1 complications, Neurofibromatosis 1 diagnosis
- Published
- 2021
- Full Text
- View/download PDF
28. Chronic Chest Pain Control after Trans-Thoracic Biopsy in Mediastinal Lymphomas.
- Author
-
Sica A, Casale B, Sagnelli C, Di Dato MT, Rispoli M, Santagata M, Buonavolontà P, Fiorelli A, Vitiello P, Caccavale S, Creta M, Salzano AM, Sagnelli E, Saracco E, Gazzerro G, Famiglietti V, Tammaro D, and Papa A
- Abstract
Chest pain following a trans-thoracic biopsy often has multiple etiologies, especially in patients with lymphomas. Pathological neuronal mechanisms integrate with an overproduction of IL-6, TNF-α, IL1-β by macrophages and monocytes, which amplifies inflammation and pain. In consideration of this complex pathogenesis, international guidelines recommend diversified analgesia protocols: thoracic epidural, paravertebral block, and systemic administration of opioids. This study reports an attempt to reduce chest pain and prevent chronic pain in 51 patients undergoing trans-thoracic biopsy for mediastinal lymphoma. The entity of pain, measured 72nd hour after biopsy by the Numerical Rating Scale (NRS), was compared with that seen at a 6th month checkpoint in 46 patients. The pain decreased in all cases. At the 6th month checkpoint, among 31 opioid-treated patients, none of the 16 patients with NRS < 6 within the 72nd hour post biopsy had developed chronic chest pain, while 8 of the 15 with higher values did ( p < 0.01). Of 10 patients undergoing thoracotomy and treated with opioids, eight had a NRS of no more than 2, of which six had no chronic pain. Of the twenty-one patients who underwent VATS biopsy and were treated with opioids, fifteen had NRS no greater than 2, of which ten had no chronic pain. Subgroups of patients biopsied under mediastinotomy or video-assisted thoracoscopic surgery (VATS) and treated with thoracic epidural analgesia (TEA) or PVB were too small for such analysis.
- Published
- 2021
- Full Text
- View/download PDF
29. A case of primary cutaneous B-cell lymphoma with immature features in an old man. Diffuse large B-cell lymphoma with immature features or B-cell lymphoblastic lymphoma?
- Author
-
Ronchi A, Zito Marino F, Vitiello P, Caccavale S, Argenziano G, Crisci S, Franco R, and Sica A
- Subjects
- Aftercare, Aged, 80 and over, DNA Nucleotidylexotransferase genetics, Diagnosis, Differential, Gene Rearrangement, Genes, myc genetics, Humans, Lymphoma, Large B-Cell, Diffuse genetics, Lymphoma, Large B-Cell, Diffuse radiotherapy, Male, Neoplasm Recurrence, Local, Neoplasm Staging, Leukocyte Common Antigens genetics, Lymphoma, Large B-Cell, Diffuse diagnosis, Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Skin Neoplasms pathology
- Abstract
Primary cutaneous B-cell lymphomas are a heterogeneous group of lymphoid neoplasms primarily occurring in the skin. Although most cases are represented by primary cutaneous follicle center cell lymphoma, primary cutaneous marginal zone lymphoma and leg-type diffuse large B-cell lymphoma, other diffuse large B-cell lymphomas and B-cell lymphoblastic lymphoma may rarely present primarily in the skin. In this setting, the presence of histopathologic and immunohistochemical features of cellular immaturity is exceedingly rare and may represent a diagnostic challenge. We present the first case of a primary cutaneous diffuse large B-cell lymphoma characterized by diminished expression of CD45, expression of TdT and rearrangement of MYC gene. The differential diagnosis mainly included B-cell lymphoblastic lymphoma, and required the genetic analysis of heavy chain (IGH) gene rearrangements., (© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
30. Primary Extra-Nodal DLBCL of Glands: Our Experiences outside Guidelines of Treatment.
- Author
-
Sica A, Santagata M, Sagnelli C, Rambaldi P, Franco R, Creta M, Vitiello P, Caccavale S, Tammaro V, Sagnelli E, and Ronchi A
- Abstract
Lymphomas usually involve lymph nodes and other lymphoid tissues, but sometimes occur in non-lymphoid organs, called extra-nodal sites. Primary diffuse extra-lymph node large B-cell lymphoma (DLBCL) of the thyroid and parotid gland have been observed rarely. According to the most accredited guidelines, primary extra-nodal DLBCL of the parotid and thyroid glands should be treated with three cycles of R-CHOP followed by radiotherapy of the involved site (ISRT). Surgery alone is not enough to treat DLBCL. We describe two unusual cases of primary extra-nodal DLBCL in elderly patients treated exclusively with surgical resection, given the inability to apply chemotherapy. Both patients achieved clinical recovery, which was maintained after a follow-up of more than 18 months, despite not having performed the indicated chemotherapy protocol. The two cases presented here, and a few others reported in the literature, should be considered exceptions to the rule, and do not allow the conclusion that surgery alone might be sufficient for complete remission.
- Published
- 2021
- Full Text
- View/download PDF
31. Real-life experience with oral oxybutynin long-term continuous therapy in severe hyperhidrosis and systematic review of the literature.
- Author
-
Briatico G, Pampena R, Fulgione E, Babino G, Giorgio CM, D'Ambra I, Caccavale S, Longo C, and Argenziano G
- Subjects
- Humans, Mandelic Acids adverse effects, Muscarinic Antagonists adverse effects, Retrospective Studies, Treatment Outcome, Hyperhidrosis diagnosis, Hyperhidrosis drug therapy, Quality of Life
- Abstract
Hyperhidrosis is a disorder of excessive sweating severely impacting on patient's quality of life (Qol). Several studies have been published about oral oxybutynin, but no studies focused on the achievement of complete clinical and Qol response. The aim of this study was to report our real-life experience with oral oxybutynin in patients with severe hyperhidrosis significantly affecting their Qol. In this cohort retrospective study, we enrolled, in a 3-year period, patients affected by severe hyperhidrosis with poor Qol, continuously treated with oral oxybutynin. Our outcome was the obtainment of complete clinical and Qol improvement. A systematic review of the literature was also performed reporting efficacy and safety of oral oxybutynin for primary hyperhidrosis. We enrolled 62 patients, of which 53 (85.5%) received a mean daily dose of 10 mg and nine (15.5%) of 5 mg. Complete clinical response was achieved in 77.4% (48/62) of cases, while complete Qol improvement occurred in 51.6% (32/62) of cases. Adverse events were only reported as mild, with dry mouth being the most frequently observed (16.1%). Kaplan-Meier survival analysis highlighted that both median clinical and Qol complete responses were reached after 1 year of continuous therapy with oral oxybutynin. The main limitation of our study is the small number of patients enrolled. Long-term therapy with oral oxybutynin for severe hyperhidrosis, continuously administered at a mean daily dosage of 5 to 10 mg, allowed the majority of our patients to reach both clinical and Qol complete improvement, without significant adverse events., (© 2021 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
32. Correlation between chronic skin ulcers dimension and burden of suffering evaluated with PRISM test.
- Author
-
Monari P, Fusano M, Moro R, Simone C, Misciali C, Baraldi C, Puviani M, Olezzi D, Caccavale S, Motolese A, and Gualdi G
- Subjects
- Chronic Disease, Humans, Prospective Studies, Surveys and Questionnaires, Quality of Life, Skin Ulcer
- Abstract
Background: In the practice of dermatology, many tools are available to help the physician measure the patient's quality of life. The Pictorial Representation of Illness and Self Measure (PRISM) is a novel and simple method to measure personal suffering. The aim of our study was to evaluate, using PRISM, whether the reduction of the ulcers' size positively correlated with an improvement of the patients' suffering., Methods: This was a multicenter national prospective study. 143 patients from five dermatological centers were enrolled in the study. At times T0 and T1 (after 1 month), the size of the ulcers was collected for each patient. At the same time, the PRISM test was also administered, in order to calculate the Self-Illness-Separation (SIS)., Results: First, a substantial decrement of the size of the ulcer seemed to correlate with a significant difference between the SIS score obtained at T0 and T1. On the contrary, the duration of the wound did not seem to influence the SIS value. No relationship between the age of the patient and the SIS value was found either., Conclusions: Our study showed that the decrease in the wound dimension positively affects the patient's suffering. In fact, ulcer's size reduction is correlated with an improvement in the patient's disease perception.
- Published
- 2021
- Full Text
- View/download PDF
33. Cutaneous Melanoma Arising in Congenital Melanocytic Nevus: A Retrospective Observational Study.
- Author
-
Caccavale S, Calabrese G, Mattiello E, Broganelli P, Ramondetta A, Pieretti G, Alfano R, and Argenziano G
- Subjects
- Adolescent, Adult, Aged, Child, Dermoscopy, Female, Humans, Italy, Male, Melanoma epidemiology, Melanoma surgery, Middle Aged, Nevus, Pigmented surgery, Prevalence, Retrospective Studies, Skin Neoplasms epidemiology, Skin Neoplasms surgery, Young Adult, Melanoma pathology, Nevus, Pigmented congenital, Nevus, Pigmented pathology, Skin Neoplasms pathology
- Abstract
Background: Congenital melanocytic nevi (CMN) are benign proliferations of melanocytes usually present at birth. The magnitude of the melanoma risk for CMN is controversial, generating an ongoing debate on the best approach to manage these lesions., Objective: To perform a retrospective, observational study with the aim to evaluate the prevalence of CMN-associated melanomas in tertiary referral centers, as well as the eventual correlation between clinical, dermoscopic, and histological features of CMN-associated melanomas., Methods: A single-center retrospective observational study was performed on all clinical and dermoscopic images of histologically confirmed melanomas arising on CMN over a 14-year period (January 2005 to March 2019)., Results: Our database included 2,159 melanomas in the considered period. Of those, 27 (1.3%) were CMN-associated melanomas. The mean age of patients with CMN-associated melanoma was 33 years (range, 11-70 years). The mean diameter of CMN-associated melanoma was 18 mm (range, 6 mm to 20 cm), and 56% were located on the back. Twenty-one (77.8%) of CMN-associated melanomas arose on small CMN (<1.5 cm), 5 (18.5%) on medium-sized CMN (1.5-19.9 cm), and 1 (3.7%) on a large/giant type (≥20 cm). The majority of CMN-associated melanomas (63%) exhibited a globular dermoscopic pattern in their benign part, while a blue-white veil and irregular blotches were the most frequent dermoscopic features in the malignant part. About three quarters of melanomas occupied 10-50% of the nevus surface. Breslow thickness was higher in melanomas involving less than 10% of nevus surface (mean thickness, 1 mm) than in those affecting 10-50 and >50% of the nevus surface (0.8 and 0.7 mm, respectively)., Conclusions: In our series, small CMN was the most frequent type of CMN-associated melanoma. Although the risk of melanoma is increasing by the increasing size of CMN, our finding is definitely related to the much higher prevalence of small CMN in the general population as compared to the prevalence of intermediate-sized and large CMN., Limitations: Small sample size, single-center experience, retrospective design., (© 2020 S. Karger AG, Basel.)
- Published
- 2021
- Full Text
- View/download PDF
34. Dermatologic surgery in centenarians.
- Author
-
Gualdi G, Monari P, Soglia S, Taddeucci P, Fimiani M, Savoia F, Melandri D, Caccavale S, Argenziano G, Calzavara-Pinton P, and Amerio P
- Subjects
- Aged, 80 and over, Humans, Dermatologic Surgical Procedures
- Published
- 2020
- Full Text
- View/download PDF
35. Dermoscopy of Syringotropic and Folliculotropic Mycosis Fungoides.
- Author
-
Tončić RJ, Radoš J, Ćurković D, Ilić I, Caccavale S, and Bradamante M
- Abstract
Competing Interests: Competing interests: The authors have no conflicts of interest to disclose.
- Published
- 2020
- Full Text
- View/download PDF
36. Reassessing the Biological Significance of Congenital Melanocytic Nevi.
- Author
-
Argenziano G, Caccavale S, Brancaccio G, Moscarella E, Piccolo V, and Lallas A
- Abstract
Competing Interests: Competing interests: The authors have no conflicts of interest to disclose.
- Published
- 2020
- Full Text
- View/download PDF
37. Primary Cutaneous B-Cell Lymphomas: An Update.
- Author
-
Vitiello P, Sica A, Ronchi A, Caccavale S, Franco R, and Argenziano G
- Abstract
Primary cutaneous B-cell lymphomas (PCBCLs) comprise a group of extranodal B-cell non-Hodgkin lymphomas B-cell derived, which primarily involve the skin without evidence of extracutaneous disease at the time of diagnosis. They include ~25% of all cutaneous lymphomas and are classified in three major subgroups (World Health Organization (WHO) 2017): primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center cell lymphoma (PCFCL), and diffuse large B-cell lymphoma, leg type (PCDLBCL, LT). This classification also includes some less common entities such as intravascular large B-cell lymphoma. Recently, WHO-EORTC added Epstein-Barr virus positive (EBV+) mucocutaneous ulcer, as a new provisional distinct entity, to cutaneous B-cell lymphomas. PCBCLs are classically characterized by patches, plaques, or nodules showing great variability for color, shape, and location. Diagnosis requires histological examination with immunohistochemical staining. In general, therapeutic options depend on the exact histological and immunohistochemical classification, disease presentation, and risk assessment. PCMZL and PCFCL are considered indolent lymphomas with a good prognosis and are associated with 5-year disease-specific survival ≥ 95%. In contrast, PCDLBCL, LT is considered an aggressive lymphoma with a survival rate in 5 years of lower than 60%. Patients with a solitary lesion or limited lesions in a single anatomical site require different treatments as compared to patients with generalized lesions or refractory disease or extracutaneous involvement. Therapeutic choice includes observation, local, or systemic therapy based on histology and disease extension. Patient management is multidisciplinary, including dermatologists, pathologists, hemato-oncologists, and radiation oncologists., (Copyright © 2020 Vitiello, Sica, Ronchi, Caccavale, Franco and Argenziano.)
- Published
- 2020
- Full Text
- View/download PDF
38. Combination of photodynamic therapy with 5-aminolaevulinic acid and microneedling in the treatment of alopecia areata resistant to conventional therapies: our experience with 41 patients.
- Author
-
Giorgio CM, Babino G, Caccavale S, Russo T, De Rosa AB, Alfano R, Fulgione E, and Argenziano G
- Subjects
- Adult, Alopecia Areata therapy, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Young Adult, Aminolevulinic Acid, Alopecia Areata drug therapy, Dry Needling, Levulinic Acids therapeutic use, Photochemotherapy, Photosensitizing Agents therapeutic use
- Abstract
Alopecia areata (AA) is a complex immune-mediated disorder, which is difficult to treat. The available treatment options seem to have limited benefit, help only some patients and have a high relapse rate. We evaluated a new therapeutic option for moderate to severe AA based on the combination of photodynamic therapy (PDT) with 5-aminolaevulinic acid (ALA) and microneedling (MN). In total, 14 patients were enrolled, and these were randomly divided into 3 groups: Group A (MN alone; n = 9), Group B (ALA-PDT alone; n = 15) and Group C (combination of MN and ALA-PDT; n = 17). All patients were treated once every 3 weeks for a total of six treatments. The best clinical outcome was achieved in Group C, with complete hair regrowth observed in three patients, and an improvement of ≥ 50% and < 50% of the treated areas obtained in seven and six patients, respectively. Our report suggests that combination of ALA-PDT with MN could be an additional therapeutic option in moderate to severe AA, as MN allows better skin penetration of ALA and subsequent indirect immunosuppression., (© 2019 British Association of Dermatologists.)
- Published
- 2020
- Full Text
- View/download PDF
39. Primary Cutaneous DLBCL Non-GCB Type: Challenges of a Rare Case.
- Author
-
Sica A, Vitiello P, Caccavale S, Sagnelli C, Calogero A, Doraro CA, Pastore F, Ciardiello F, Argenziano G, Reginelli A, Cappabianca S, Franco R, and Ronchi A
- Abstract
Several types of B-cell lymphomas, including both primary cutaneous lymphomas and systemic lymphomas, may affect the skin, with partially overlapping clinical, morphological and immunohistochemical features. Currently, the World Health Organization (WHO) classification of primary cutaneous B-cell lymphomas does not include diffuse large B-cell lymphomas (DLBCL) and considers leg-type DLBCL the only primary cutaneous DLBCL. Here we report the case of a 72-year-old white woman with a primary cutaneous neoplasm comprised of large cells with round nuclei, irregularly clumped chromatin and one or more inconspicuous nucleoli. The immunohistochemistry demonstrated positivity for CD20 and MUM1, with no significant genetic translocations detected by fluorescence in-situ hybridization. After staging, we considered this neoplasm a primary cutaneous DLBCL with a non-germinal center phenotype, not otherwise specified, inconsistent with a leg-type DLBCL. Because of this view, we underscore the need for greater knowledge of the molecular landscape of B-cell lymphomas in order to reconsider the classification of such neoplasms in the skin., Competing Interests: Conflict of interest Conflict of interest statement: All the authors of the manuscript declare that they have no conflict of interest in connection with this paper., (© 2020 Antonello Sica et al., published by De Gruyter.)
- Published
- 2020
- Full Text
- View/download PDF
40. When basal cell carcinomas became giant: an Italian multicenter study.
- Author
-
Gualdi G, Monari P, Calzavara-Pinton P, Caravello S, Fantini F, Bornacina C, Specchio F, Argenziano G, Simonetti V, Caccavale S, La Montagna M, Cecchi R, Landi C, Simonacci M, Dusi D, Puviani M, Zucchi A, Zampieri P, Inchaurraga MAG, Savoia F, Melandri D, Capo A, and Amerio P
- Subjects
- Aged, Aged, 80 and over, Carcinoma, Basal Cell epidemiology, Carcinoma, Basal Cell surgery, Carcinoma, Basal Cell therapy, Female, Humans, Male, Middle Aged, Neoplasm Staging, Skin Neoplasms epidemiology, Skin Neoplasms surgery, Skin Neoplasms therapy, Carcinoma, Basal Cell pathology, Skin Neoplasms pathology
- Abstract
Background: Giant basal cell carcinoma (GBCC) is a basal cell carcinoma (BCC) enlarged in a diameter more than 5 cm. Since GBCCs are a highly infrequent entity and the occurrence rate is approximately 0.5-1% out of all BCC types, only anecdotal cases are reported, and causes and characteristics inducing development of this tumor are not defined., Objectives: Evaluate causative factors and clinico-histological characteristics of GBCCs., Methods: The study is a 6-month, hospital-based case series study performed in 12 Italian dermatologic centers., Results: A total of 59 cases and 458 control BCCs were collected. No significant differences existed between the two groups if we take into account social or cultural factors. The average duration of GBCCs is considerably longer than controls. GBCCs are located on unexposed areas while BCCs are on areas not usually covered by clothes. Superficial histological subtype was more frequent in the BCCs group, while infiltrative in GBCCs. GBCCs showed significantly higher local invasiveness, and greater metastatic capacity. More than half of GBCCs had been previously treated with one or more treatments., Conclusions: Patients with GBCCs appear to belong to two categories: (i) those who present with GBCC due to delay in accessing medical attention, and (ii) those who have BCCs previously treated with inappropriate strategies. Only very few cases can be carried out with intrinsic biological features of tumor aggressiveness. Social and cultural conditions do not appear to be involved in the development of GBCCS. These observations may help clinicians in selecting correct therapeutic strategies in the treatment of BCCs, which give rise to GBCC., (© 2019 The International Society of Dermatology.)
- Published
- 2020
- Full Text
- View/download PDF
41. Italian Guidelines in diagnosis and treatment of alopecia areata.
- Author
-
Rossi A, Muscianese M, Piraccini BM, Starace M, Carlesimo M, Mandel VD, Alessandrini A, Calvieri S, Caro G, D'arino A, Federico A, Magri F, Pigliacelli F, Amendolagine G, Annunziata MC, Arisi MC, Astorino S, Babino G, Bardazzi F, Barruscotti S, Belloni Fortina A, Borghi A, Bruni F, Caccavale S, Calzavara-Pinton P, Cameli N, Cardone M, Carugno A, Coppola R, Dattola A, De Felici Del Giudice MB, Di Cesare A, Dika E, Di Nunno D, D'ovidio R, Fabbrocini G, Feliciani C, Fulgione E, Galluzzo M, Garcovich S, Garelli V, Guerriero C, Hansel K, La Placa M, Lacarrubba F, Lora V, Marinello E, Megna M, Micali G, Misciali C, Monari P, Monfrecola G, Neri I, Offidani A, Orlando G, Papini M, Patrizi A, Piaserico S, Rivetti N, Simonetti O, Stan TR, Stingeni L, Talamonti M, Tassone F, Villa L, Vincenzi C, and Fortuna MC
- Subjects
- Alopecia Areata diagnosis, Alopecia Areata immunology, Autoimmune Diseases diagnosis, Autoimmune Diseases immunology, Evidence-Based Medicine, Humans, Italy, Alopecia Areata therapy, Autoimmune Diseases therapy, Hair Follicle immunology
- Abstract
Alopecia areata (AA) is an organ-specific autoimmune disorder that targets anagen phase hair follicles. The course is unpredictable and current available treatments have variable efficacy. Nowadays, there is relatively little evidence on treatment of AA from well-designed clinical trials. Moreover, none of the treatments or devices commonly used to treat AA are specifically approved by the Food and Drug Administration. The Italian Study Group for Cutaneous Annexial Disease of the Italian Society of dermatology proposes these Italian guidelines for diagnosis and treatment of Alopecia Areata deeming useful for the daily management of the disease. This article summarizes evidence-based treatment associated with expert-based recommendations.
- Published
- 2019
- Full Text
- View/download PDF
42. Efficacy of Microneedling and Photodynamic Therapy in Vitiligo.
- Author
-
Giorgio CM, Caccavale S, Fulgione E, Moscarella E, Babino G, and Argenziano G
- Subjects
- Adult, Humans, Middle Aged, Needles, Pilot Projects, Treatment Outcome, Young Adult, Photochemotherapy methods, Punctures, Ultraviolet Therapy methods, Vitiligo therapy
- Published
- 2019
- Full Text
- View/download PDF
43. Dermoscopic characterization of folliculotropic mycosis fungoides selectively localized on trunk and limbs.
- Author
-
Caccavale S, Vitiello P, Franco R, Panarese I, Ronchi A, Sica A, Jurakic Toncic R, Alfano R, and Argenziano G
- Subjects
- Bexarotene therapeutic use, Biopsy, Dermoscopy, Diagnosis, Differential, Extremities, Humans, Lymphoma diagnosis, Male, Middle Aged, Mycosis Fungoides pathology, Mycosis Fungoides therapy, PUVA Therapy, Skin diagnostic imaging, Skin pathology, Skin Neoplasms pathology, Skin Neoplasms therapy, Torso, Treatment Outcome, Mycosis Fungoides diagnostic imaging, Skin Neoplasms diagnostic imaging
- Published
- 2019
- Full Text
- View/download PDF
44. Curettage + microneedling + topical ALA-PDT for the treatment of acral resistant warts: Our experience.
- Author
-
Caccavale S, Iocco A, Pieretti G, Alfano R, and Argenziano G
- Subjects
- Adolescent, Adult, Aminolevulinic Acid administration & dosage, Aminolevulinic Acid adverse effects, Aminolevulinic Acid therapeutic use, Combined Modality Therapy, Curettage adverse effects, Female, Humans, Male, Middle Aged, Photochemotherapy adverse effects, Photosensitizing Agents administration & dosage, Photosensitizing Agents adverse effects, Warts drug therapy, Young Adult, Aminolevulinic Acid analogs & derivatives, Curettage methods, Needles, Photochemotherapy methods, Photosensitizing Agents therapeutic use, Warts therapy
- Abstract
Background: Cutaneous warts are an extremely common problem, whose eradication can be challenging. Topical PDT involves applying a porphyrin precursor, 5-aminolevulinic acid (ALA) or methyl aminolevulinate (MAL) to the affected area. ALA-PDT has been well documented to be successful in the treatment of recalcitrant warts. PDT has a limited role in the treatment of thicker lesions because the photosensitizer does not penetrate keratotic lesions well, though this is vehicle dependent., Objective: The aim of this study was to evaluate the efficacy and safety of curettage + microneedling + ALA-PDT for the treatment of resistant acral warts. We hypothesized that microneedling may increase the efficacy of PDT, providing a channel to deliver the ALA to deeper areas of warts., Methods: Our study was carried out between November 2017 and July 2018. Eligible participants had one or more resistant plantar or palmar warts. Thirteen patients were recruited. They underwent a thorough curettage, followed by the application of 5-ALA 10% cream on the wart, and by microneedling. Later, the pricked skin was covered for three hours by an occlusive polyurethane dressing, and finally irradiated with a red-light source. Patients performed one session every three weeks for a total of three cycles., Results: After 3 treatments of curettage + microneedling + ALA-PDT, 11 patients (84.6%) showed complete remission (defined as complete disappearance of their warts). One patient (7.7%) showed partial remission (defined as greater than 50% decrease in the wart area) after 3 sessions; this patient needed other 2 sessions to achieve complete remission. The mean follow-up period after healing was 4.3 months. Adverse effects were recorded., Conclusion: We have demonstrated, for the first time to our knowledge, that the combination of curettage + microneedling + topical ALA-PDT may offer an effective and safe alternative for the treatment of acral resistant warts, even when PDT alone has already been insufficient., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
45. Dermoscopy and reflectance confocal microscopy of osteoclastic deep benign fibrous histiocytoma.
- Author
-
Caccavale S, Vitiello P, Agozzino M, Mascolo M, Ciancia G, and Argenziano G
- Subjects
- Dermoscopy methods, Female, Histiocytoma, Benign Fibrous pathology, Humans, Microscopy, Confocal methods, Skin Neoplasms pathology, Young Adult, Histiocytoma, Benign Fibrous diagnosis, Osteoclasts metabolism, Skin Neoplasms diagnosis
- Published
- 2019
- Full Text
- View/download PDF
46. The use of in vivo reflectance confocal microscopy for the diagnosis of melanoma.
- Author
-
Agozzino M, Moscarella E, Babino G, Caccavale S, Piccolo V, and Argenziano G
- Subjects
- Dermoscopy methods, Humans, Melanoma pathology, Sensitivity and Specificity, Skin Neoplasms pathology, Melanoma diagnostic imaging, Microscopy, Confocal methods, Skin Neoplasms diagnostic imaging
- Abstract
Introduction: The use of reflectance confocal microscopy (RCM) for imaging the skin non-invasively raised constantly during the last decade. One of the main field of application is skin cancer diagnosis, and in particular melanoma diagnosis. Several studies have investigated the diagnostic accuracy of RCM as compared to dermoscopic examination, and its value in enhancing early diagnosis of dermoscopic difficult melanomas. Areas covered: The purpose of this paper was to review the principles behind RCM image acquisition as well as to describe and discuss key RCM features of melanoma. Moreover, we conducted a literature search in order to highlight the current available evidence about RCM sensitivity and specificity in the diagnosis of melanoma. Expert commentary: During the last decade, we assisted at the increasing interest in non invasive imaging tools for the diagnosis of skin cancer. RCM is one of the most studied of a series of diagnostic methods that are emerging in the field of melanoma imaging. Most probably in the future, RCM will be more frequently available in tertiary referral centres, thus the knowledge of the pros and contra of the tool and its clinical applicability is of upmost importance in order to allow correct referrals with the final aim of improving diagnostic accuracy.
- Published
- 2019
- Full Text
- View/download PDF
47. Association Between Melanoma Risk and Height: A Narrative Review.
- Author
-
Vena GA, Cassano N, Caccavale S, and Argenziano G
- Abstract
The link between anthropometric indices, including height, and cancer risk and/or progression has attracted considerable interest in recent years. Adult height results from the complex interplay between genetic, hormonal, nutritional, and other environmental factors and has been found to contribute to the risk of several selected malignancies, although it has not been implicated as a real cause per se. A number of studies have investigated the height-melanoma relationship, showing controversial results so far. In this review, we summarize the epidemiological data regarding the association between height and melanoma risk and analyze the potential underlying mechanisms., Competing Interests: Competing interests: The authors have no conflicts of interest to disclose.
- Published
- 2019
- Full Text
- View/download PDF
48. Epidemiology of pyoderma gangrenosum: Results from an Italian prospective multicentre study.
- Author
-
Monari P, Moro R, Motolese A, Misciali C, Baraldi C, Fanti PA, Caccavale S, Puviani M, Olezzi D, Zampieri P, Trevisan G, Nan K, Fiorentini C, Pellacani G, and Gualdi G
- Subjects
- Female, Humans, Incidence, Italy epidemiology, Male, Prospective Studies, Retrospective Studies, Epidemiologic Measurements, Pyoderma Gangrenosum epidemiology
- Abstract
Pyoderma gangrenosum (PG) is a neutrophilic dermatosis characterised by painful, necrotic ulcerations. PG is described as a rare disease: the world-wide incidence is estimated to be around 3 to 10 cases per million population per year. These estimations are based mostly on case reports and retrospective case series; there are no prospective, multicentre studies on the matter. The apparent rarity of PG is in contrast with our clinical perception as dermatologists: in our opinion, PG is not so uncommon. Therefore, we decide to investigate the epidemiology of PG in the Italian population and confirm our clinical suspicions that it is not an orphan disease. We enrolled all patients diagnosed with PG in 8 Italian Dermatological Departments from 1st October 2014 to 1st November 2015, and we recorded their features. Our data, collected from 64 patients, are in accordance with those of the published literature regarding the epidemiology and features of PG. In an Italian population of roughly 8 million inhabitants of 7 provinces, we found an incidence of 5.17 new cases per million population per year. Unlike our predictions before the study, we confirmed the world-wide incidence of PG. To our knowledge, this is the first observational, multicentre study on PG. We hope that it provides a stimulus for further researches on PG and for the creation of an Italian register., (© 2018 Medicalhelplines.com Inc and John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
49. Early dermoscopic sign of folliculotropism in patients with mycosis fungoides.
- Author
-
Toncic RJ, Drvar DL, Bradamante M, Rados J, Jerkovic-Gulin S, Caccavale S, and Argenziano G
- Abstract
Competing Interests: Competing interests: The authors have no conflicts of interest to disclose.
- Published
- 2018
- Full Text
- View/download PDF
50. Obligate and facultative paraneoplastic dermatoses: an overview.
- Author
-
Caccavale S, Brancaccio G, Agozzino M, Vitiello P, Alfano R, and Argenziano G
- Abstract
Dermatological paraneoplastic syndromes are a group of cutaneous diseases associated with malignancy, but not directly related to the primary tumor itself or to its metastases. It is of utmost importance for the dermatologist to recognize the major cutaneous paraneoplastic syndromes to diagnose the underlying tumors that trigger them as early as possible. In this overview, skin conditions that are highly correlated with malignancy, whose recognition implies a mandatory investigation of internal cancer, are described., Competing Interests: Competing interests: The authors have no conflicts of interest to disclose.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.